SAN DIEGO Weekly tirzepatide injections in adults with type 2 diabetes and overweight or obesity safely led to 12.8%-14.7% in-trial weight loss after 72 weeks in the SURMOUNT-2 pivotal trial, a findi… [+6492 chars]Read More
SURMOUNT2 Tirzepatide Rings Up Major Weight Loss in T2D Medscape
